

**TABLE 90** Summary results for the direct meta-analysis and results of the mixed-treatment comparison (HR, 95% CI) 1-year survival for trials comparing chemotherapy vs chemotherapy in population 1: population with squamous disease

Reference treatment vs comparator	Direct meta-analysis 1 (n = 17) HR (95% CI)	Mixed-treatment comparison 1 (n = 17) HR (95% CI)	Mixed-treatment comparison A (n = 15), HR (95% CI)	Mixed-treatment comparison B (n = 17), HR (95% CI)	Mixed-treatment comparison C (n = 17), HR (95% CI)	Mixed-treatment comparison D (n = 16), HR (95% CI)	Mixed-treatment comparison E (n = 16), HR (95% CI)
GEM + PLAT vs VNB + PLAT <sup>43,45,49,50,54,55,57,58</sup>	0.90 (0.81 to 1.02)	0.93 (0.83 to 1.05)	0.94 (0.83 to 1.06)	0.94 (0.84 to 1.06)	0.95 (0.85 to 1.06)	0.93 (0.83 to 1.06)	0.93 (0.83 to 1.05)
GEM + PLAT vs PAX + PLAT <sup>43,46,47,56,57,60</sup>	1.00 (0.90 to 1.10)	0.96 (0.85 to 1.08)	0.96 (0.85 to 1.08)	0.94 (0.84 to 1.06)	0.96 (0.86 to 1.07)	0.96 (0.85 to 1.08)	0.96 (0.85 to 1.08)
GEM + PLAT vs DOC + PLAT <sup>47</sup>	0.86 (0.69 to 1.09) <sup>a</sup>	0.97 (0.83 to 1.15)	0.97 (0.79 to 1.17)	0.91 (0.77 to 1.07)	0.91 (0.77 to 1.07)	0.97 (0.81 to 1.16)	0.97 (0.81 to 1.15)
VNB + PLAT vs PAX + PLAT <sup>43,48,51,57</sup>	0.89 (0.78 to 1.01)	1.03 (0.89 to 1.17)	1.02 (0.88 to 1.18)	1 (0.87 to 1.14)	1.02 (0.89 to 1.16)	1.03 (0.89 to 1.18)	1.03 (0.89 to 1.18)
VNB + PLAT vs DOC + PLAT <sup>44,52,53,59</sup>	1.09 (0.97 to 1.23)	1.04 (0.91 to 1.19)	1.04 (0.86 to 1.23)	0.96 (0.83 to 1.11)	0.96 (0.83 to 1.1)	1.05 (0.88 to 1.22)	1.04 (0.89 to 1.2)
PAX + PLAT vs DOC + PLAT <sup>47</sup>	1.01 (0.79 to 1.29) <sup>a</sup>	1.02 (0.85 to 1.21)	1.01 (0.81 to 1.24)	0.96 (0.8 to 1.16)	0.94 (0.79 to 1.13)	1.02 (0.83 to 1.23)	1.01 (0.84 to 1.22)

<sup>a</sup> Direct evidence available. Direct meta-analysis A and mixed-treatment comparison A: sensitivity analysis excluding Chen *et al.*<sup>52</sup> (<24 months follow-up time) and Tan *et al.*<sup>59</sup> (used six cycles of chemotherapy). Direct meta-analysis B and mixed-treatment comparison B: sensitivity analysis using data from PAX + CIS instead of PAX + CARB from the Schiller *et al.* trial.<sup>47</sup> Direct meta-analysis C and mixed-treatment comparison C: sensitivity analysis using data from DOC + CARB instead of DOC + CIS from the Fossella *et al.* trial.<sup>44</sup> Direct meta-analysis D and mixed-treatment comparison D: sensitivity analysis excluding Tan *et al.*<sup>59</sup> (used six cycles of chemotherapy). Direct meta-analysis E and mixed-treatment comparison E: sensitivity analysis excluding Chen *et al.*<sup>52</sup> (<24 months follow-up time). This affects VNB + PLAT vs DOC + PLAT pair-wise comparison.

A HR > 1 favours the reference treatment and a HR < 1 favours the comparator treatment.